How does startup funding rounds work?

Startup funding rounds are the structured “chapters” of raising capital. In each chapter, you trade something (usually equity, meaning ownership shares) for money to hit the next set of milestones. The confusing part is that rounds aren’t just about cash—they’re about risk reduction: each round is supposed to prove something important (market demand, repeatable sales, scalable growth) so the next investor will pay a higher price.

The core mechanics: what a “round” actually is

A funding round is a financing event where new money comes into the company under a defined set of terms. Those terms typically include:

• Instrument: how the money converts into ownership. Common options are priced equity (shares issued now) or convertible instruments (convert later).
• Valuation: what the company is “worth” for the purpose of the deal. In a priced round you’ll see pre-money valuation (value before the new cash) and post-money valuation (pre-money + new cash).
• Dilution: the percentage of the company founders and existing shareholders give up because new shares are issued.
• Governance: who gets board seats, voting rights, and protective provisions (rules that require investor approval for major actions).

Most early rounds are either:

• Convertible note: a loan that converts into equity later, usually with a discount (e.g., 20%) and/or a valuation cap (a maximum price at which it converts).
• SAFE (Simple Agreement for Future Equity): similar to a note but typically without interest or maturity date; it converts later based on a cap/discount.
• Priced equity round: you set a valuation now and sell shares now (common from Seed onward, almost always by Series A).

Typical round stages (and what investors expect)

Names vary by geography and sector, but the logic is consistent: each stage funds the work needed to reach the next “proof point.”

Pre-seed

Goal: prove the problem is real and you can build a credible solution. This is often about customer discovery and a prototype, not scale.

• Common evidence: interviews, waitlist, pilot LOIs (letters of intent), early prototype, strong founder-market fit.
• Common instruments: SAFE/convertible note.
• Typical use of funds: 6–18 months of runway (runway = months until you run out of cash), build MVP (minimum viable product), initial regulatory/clinical planning if relevant.

Seed

Goal: prove you can deliver value to customers and that there’s a repeatable way to acquire them. Seed is often where you move from “it works” to “people pay / adopt reliably.”

• Common evidence: early revenue or strong usage, successful pilots, retention signals, clear ICP (ideal customer profile), a believable go-to-market plan.
• Common instruments: priced equity increasingly common; SAFEs still used.
• Typical use of funds: hire initial team (engineering + sales/marketing), tighten product, build repeatable acquisition channels.

Series A

Goal: prove a scalable growth model. Series A investors want to see that if you put $1 in, you can reliably get more than $1 out over time (unit economics).

• Common evidence: consistent growth, strong retention, improving CAC payback (customer acquisition cost payback), clear sales motion, expanding pipeline.
• Common instruments: priced equity with a full term sheet.
• Typical use of funds: scale go-to-market, expand product, build management layer, invest in systems (analytics, finance, compliance).

Series B/C and beyond

Goal: scale aggressively, expand markets, and optimize efficiency. Later rounds are more about execution and less about existential product risk.

• Common evidence: predictable growth, strong gross margins (varies by business), multi-channel acquisition, mature KPIs.
• Common instruments: priced equity; sometimes structured terms.

Valuation and dilution: the math founders must understand

Two numbers drive most founder outcomes: valuation and dilution. Here’s the simplest way to think about it.

Pre-money vs post-money (with an example)

Suppose you raise $2M at a $8M pre-money valuation.

• Post-money = $8M + $2M = $10M
• New investors own $2M / $10M = 20% of the company (before considering option pool changes).

That 20% is the “headline dilution” from the round. In practice, dilution can be higher because of the option pool (shares reserved for employee equity). Investors often require the option pool to be “topped up” before they invest, which effectively dilutes founders more.

Why the option pool matters

An option pool is a set of shares reserved for hiring (e.g., 10–15% is common early, but it varies). If you don’t model this, you can be surprised when a term sheet says “create a 10% option pool pre-money.” That means the pool is carved out of the pre-money cap table, usually impacting founders most.

Convertible rounds: caps and discounts in plain language

If you raise on a SAFE with a valuation cap, you’re saying: “When this converts later, treat my money as if it invested at no more than X valuation.” A discount says: “Convert at a cheaper price than the new investors (e.g., 20% off).” These terms reward early risk-taking.

Key founder takeaway: convertible instruments delay the valuation conversation, but they don’t remove it—they push it into the future and can stack up if you do multiple SAFE/note rounds.

What happens during a round: the step-by-step process

Funding rounds feel mysterious until you break them into a pipeline, similar to a clinical workflow or engineering lifecycle.

1. Preparation: define your milestones, build a fundraising narrative, update your pitch deck, and clean up your cap table (ownership table).
2. Targeting: build a list of investors who actually invest at your stage and in your type of business.
3. Outreach + meetings: you run a process (often 3–6 weeks for early rounds, but it varies) to create momentum.
4. Term sheet: a non-binding summary of key terms (valuation, amount, board, liquidation preference, option pool expectations).
5. Due diligence: investors verify claims—customer calls, financial review, IP review, security/compliance checks as relevant.
6. Definitive documents: the actual legal agreements (stock purchase agreement, investor rights, etc.).
7. Close: money wires, shares are issued, cap table updates, and you start investor reporting.

Common terms you’ll see (and why they matter)

You don’t need an MBA, but you do need to recognize a few terms that materially affect outcomes.

• Liquidation preference: who gets paid first in an exit. A common structure is “1x non-participating,” meaning investors typically get their money back first or convert to equity—whichever is better. More complex preferences can change founder payouts dramatically.
• Pro-rata rights: gives investors the right to maintain their ownership in future rounds.
• Board seat: governance power. Early on, keep the board small and functional.
• Protective provisions: investor vetoes on major actions (issuing new shares, selling the company, taking on debt).
• Vesting: founders often have vesting schedules (e.g., 4 years with a 1-year cliff is common). It protects the company if a founder leaves early.

If you’re technical/medical/scientific, treat the term sheet like a protocol: small wording changes can produce large downstream effects. Get qualified legal help for priced rounds.

What to do next

• Model dilution for 2–3 scenarios (SAFE vs priced round; with and without an option pool top-up) so you know what you’re trading.
• Write your milestone plan for the next 12–18 months and tie each milestone to a budget (headcount, tooling, trials/pilots, marketing).
• Pressure-test your round readiness by documenting the proof you have (revenue, pilots, retention, LOIs) and what’s still assumption.
• Run a lightweight investor pipeline with weekly goals (e.g., 10 new outreaches, 5 meetings, 1 partner meeting) and track it like a sales funnel.
• Use StartupLaby tools to sharpen your story and numbers: /launchpad, /finances, /Competitor_study, /roast.